Nabriva Therapeutics plc – (NASDAQ:NBRV) reached a new 52-week high and low during trading on Friday . The company traded as low as $4.39 and last traded at $4.46, with a volume of 91467 shares changing hands. The stock had previously closed at $4.57.
A number of equities research analysts have commented on NBRV shares. Cantor Fitzgerald set a $16.00 target price on Nabriva Therapeutics and gave the company a “buy” rating in a report on Friday, March 16th. Zacks Investment Research raised Nabriva Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday. Morgan Stanley started coverage on Nabriva Therapeutics in a report on Wednesday, January 17th. They issued an “overweight” rating and a $10.00 target price for the company. Bank of America started coverage on Nabriva Therapeutics in a report on Wednesday, March 21st. They issued a “buy” rating and a $10.00 target price for the company. Finally, ValuEngine downgraded Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.69.
The company has a market capitalization of $167.79, a PE ratio of -1.80 and a beta of 1.77.
Several large investors have recently added to or reduced their stakes in NBRV. Millennium Management LLC acquired a new position in shares of Nabriva Therapeutics during the 4th quarter worth $5,188,000. Alyeska Investment Group L.P. acquired a new position in Nabriva Therapeutics in the 3rd quarter valued at about $5,724,000. Prosight Management LP acquired a new position in Nabriva Therapeutics in the 4th quarter valued at about $2,939,000. Pura Vida Investments LLC acquired a new position in Nabriva Therapeutics in the 3rd quarter valued at about $3,481,000. Finally, Rubric Capital Management LP acquired a new position in Nabriva Therapeutics in the 3rd quarter valued at about $2,457,000. 55.56% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3339844/nabriva-therapeutics-nbrv-hits-new-1-year-high-and-low-at-4-39.html.
About Nabriva Therapeutics
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.